SB 399885 hydrochloride |
| Catalog No.GC15660 |
5-HT6 antagonist
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 402713-81-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SB-399885 hydrochloride is a 5-HT6 receptor antagonist.
Compare with the control vehicle SB-399885 hydrochloride 10 mg/kg significantly increases wakefulness (W) (F(3,15)=3.32, P<0.05) while slow wave sleep (SWS), rapid-eye-movement sleep (REMS) and the number of REM periods are reduced (F(3,15)=4.0, P<0.01; F(3,15)=3.14, P<0.05 and F(3,15)=2.62, P<0.05, respectively). Analysis of sleep variables in 2-h blocks shows that SB-399885 hydrochloride 10 mg/kg increases W (F(3,15)=5.48, P<0.01) and reduces SWS (F(3,15)=5.42, P<0.01) and REMS (F(3,15)= 4.05, P<0.01) during the first 2-h period. SB-399885 hydrochloride 5 and 10 mg/kg augment light sleep over the first (F(3,15)=3.46,P<0.01 and F(3,15)= 3.65, P<0.01, respectively) and the second (F(3,15)=3.23, P<0.05 and F(3,15)=3.08, P<0.05, respectively) 2-h recording periods. SB-399885 hydrochloride 10 mg/kg significantly increases REMS latency (F(3,15)=3.60, P<0.01) and reduces the number of REM periods during the first 2-h of recording (F(3,15)=3.88, P<0.01)[1].
References:
[1]. Monti JM, et al. Effects of the 5-HT6 receptor antagonists SB-399885 and RO-4368554 and of the 5-HT(2A) receptor antagonist EMD 281014 on sleep and wakefulness in the rat during both phases of the light-dark cycle. Behav Brain Res. 2011 Jan 1;216(1):381-8.
Animal experiment: | Twelve male Wistar rats weighing 350 to 400 g at the time of surgery are used. SB-399885 hydrochloride 2.5, 5 and 10 mg/kg or vehicle (1% aqueous solution of Tween 80) (n=6) are administered intraperitoneally in animals adapted to a 12 h dark/12 h light cycle for 4 weeks, starting 2 h after the beginning of the dark period. Each animal receives all 12 treatments. Recordings are begun 15 min later and continued for 6 h. The control solution and SB-399885 hydrochloride are given at least three days apart[1]. |
References: [1]. Monti JM, et al. Effects of the 5-HT6 receptor antagonists SB-399885 and RO-4368554 and of the 5-HT(2A) receptor antagonist EMD 281014 on sleep and wakefulness in the rat during both phases of the light-dark cycle. Behav Brain Res. 2011 Jan 1;216(1):381-8. | |
| Cas No. | 402713-81-9 | SDF | |
| Chemical Name | N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-(piperazin-1-yl)benzenesulfonamide hydrochloride | ||
| Canonical SMILES | COC1=C(N2CCNCC2)C=C(S(NC3=CC(Cl)=CC(Cl)=C3OC)(=O)=O)C=C1.Cl | ||
| Formula | C18H21Cl2N3O4S.HCl | M.Wt | 482.81 |
| Solubility | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,PBS (pH 7.2): 10 mg/ml | Storage | Desiccate at RT |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0712 mL | 10.356 mL | 20.7121 mL |
| 5 mM | 0.4142 mL | 2.0712 mL | 4.1424 mL |
| 10 mM | 0.2071 mL | 1.0356 mL | 2.0712 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 4 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *